APL-3007, pegcetacoplan (APL-2)

Phase 2Small molecule

APL-3007, pegcetacoplan (APL-2) is one of 34 small molecule programs targeting Geographic Atrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Geographic AtrophyActive, not recruiting

Geographic Atrophy Secondary to Age-Related Macular DegenerationRecruiting

Geographic AtrophyPhase 2

Active, not recruiting

Geographic Atrophy Secondary to Age-Related Macular DegenerationPhase 2

Recruiting

Competition

Competitive Landscape

38 competitors in Geographic Atrophy

#DrugCompanyPhaseTrials

Lucentis

Roche

Approved

2 2

Eylea

Regeneron

Approved

1 3

Izervay

Astellas

Approved

3 4

Empaveli

Apellis Pharmaceuticals

Phase 3

3 5

Cemdisiran

Tecfidera

1 7

Farxiga

AstraZeneca

Phase 2

1 8

Rapamune

PPrism Pharmaceuticals

Phase 2

1 9

Xylocaine

MMEDRx USA, Inc.

Phase 2

1 10

Glucophage

EMD Serono

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT07215390

Clinical

Trials by Indication[1]

Geographic Atrophy Secondary to Age-related Macular Degeneration1 trial

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration

Recruiting· Apellis Pharmaceuticals logo

Apellis Pharmaceuticals·Phase 2·NCT07215390·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for APL-3007, pegcetacoplan (APL-2). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APL-3007, pegcetacoplan (APL-2) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APL-3007, pegcetacoplan (APL-2). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Apellis Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Apellis Pharmaceuticals

APL-3007, pegcetacoplan (APL-2)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Geographic Atrophy Secondary to Age-related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News